MedPath

FDA Advisory Committee to Review Elamipretide for Barth Syndrome

  • The FDA's Cardiovascular and Renal Drugs Advisory Committee will review elamipretide for Barth syndrome on October 10, 2024.
  • Elamipretide, a first-in-class mitochondria-targeted therapeutic, is under review as a potential treatment for this ultra-rare genetic condition.
  • The FDA has granted priority review to the NDA for elamipretide, with a PDUFA action date set for January 29, 2025.
  • Barth syndrome affects approximately 150 individuals in the U.S. and is associated with reduced life expectancy, with no current FDA-approved therapies.
Stealth BioTherapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) will convene its Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on October 10, 2024, to evaluate the New Drug Application (NDA) for elamipretide. Elamipretide is a first-in-class, mitochondria-targeted therapeutic being considered for the treatment of Barth syndrome, an ultra-rare and progressive genetic condition. The NDA has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) action date of January 29, 2025.

Elamipretide's Potential Impact on Barth Syndrome

Barth syndrome is characterized by cardiac abnormalities, muscle weakness, debilitating fatigue, heart failure, recurrent infections, and delayed growth. The condition primarily affects males and is estimated to impact 1 in 1,000,000 males worldwide, with approximately 150 individuals affected in the United States. A significant concern is the reduced life expectancy associated with Barth syndrome; approximately 85% of early deaths occur by age 5. Currently, there are no FDA- or EMA-approved therapies available for patients with Barth syndrome.

Addressing Unmet Needs

"We are grateful to the patients, families, and physicians who participated in the studies that supported this new drug application, as well as to the patient and medical community members who requested a review of elamipretide as the first potential therapy for Barth syndrome," said Reenie McCarthy, Chief Executive Officer of Stealth BioTherapeutics. "We look forward to meeting with the Cardiovascular and Renal Drugs Advisory Committee to discuss elamipretide's potential to improve the lives of individuals living with Barth syndrome, a devastating disease with a significant and urgent unmet medical need."

Elamipretide's Development Pipeline

Elamipretide has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, as well as Orphan Drug Designation from the EMA for the treatment of Barth syndrome. Beyond Barth syndrome, elamipretide is also in Phase 3 trials for primary mitochondrial myopathy, with pivotal data expected by the end of 2024, and for dry age-related macular degeneration. Stealth BioTherapeutics is also evaluating bevemipretide (SBT-272), a second-generation clinical-stage candidate, in a topical ophthalmic formulation for dry age-related macular degeneration.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Gears Up for Critical Decisions on Alzheimer's, Breast Cancer, and Neurological Therapies in Early 2025

The FDA is set to decide on Biogen and Eisai's Leqembi for monthly intravenous maintenance in early Alzheimer's disease, potentially improving patient convenience.

Solid Biosciences' SGT-212 Receives FDA Fast Track Designation for Friedreich's Ataxia Treatment

Solid Biosciences' SGT-212, a dual-route gene therapy for Friedreich's ataxia (FA), has received Fast Track designation from the FDA, expediting its development and review process.

FDA Wraps Up 2024 with Key Approvals for Drugs Targeting Various Conditions

The FDA approved Vertex's Alyftrek for cystic fibrosis, offering improved dosing and potential market exclusivity.

Applied Therapeutics Awaits FDA Decision on Govorestat for Galactosemia

Applied Therapeutics is seeking FDA approval for govorestat, a novel aldose reductase inhibitor, for the treatment of galactosemia, a rare metabolic disorder.

Disc Medicine Announces End-of-Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine will host a conference call on November 4 to discuss feedback from the FDA regarding the end-of-Phase 2 meeting for bitopertin.

FDA Raises Doubts About Stealth BioTherapeutics' Elamipretide for Barth Syndrome

The FDA has expressed significant concerns regarding the effectiveness of Stealth BioTherapeutics' elamipretide for treating Barth syndrome.

FDA Advisory Committee Backs Elamipretide for Barth Syndrome Despite Data Concerns

The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in favor of elamipretide for treating Barth syndrome, a rare genetic disorder.

FDA Advisory Committee to Review Rare Disease Treatment Amid Efficacy Concerns

An FDA advisory committee will convene to evaluate a rare disease drug, a decision influenced by strong advocacy from patient communities.

FDA Accepts Stealth BioTherapeutics' NDA for Elamipretide in Barth Syndrome

The FDA has accepted Stealth BioTherapeutics' NDA for elamipretide, a potential first-in-class therapy for Barth syndrome, a rare genetic condition.

FDA Accepts Elamipretide NDA for Barth Syndrome Treatment

The FDA has accepted Stealth BioTherapeutics' NDA for elamipretide in treating Barth syndrome, a rare genetic condition with no approved therapies.

Reference News

[1]
Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review ... - BioSpace
biospace.com · Sep 9, 2024

FDA to review Stealth BioTherapeutics' elamipretide for Barth syndrome on October 10, 2024, with a PDUFA date of January...

[2]
Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review ... - PR Newswire
prnewswire.com · Sep 9, 2024

Stealth BioTherapeutics announces FDA's advisory committee meeting on October 10, 2024, to evaluate elamipretide, a pote...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy